dismiss

Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

Researchers find new PET tracer that better detects melanoma than 18F-FDG 18F-P3BZA could become the new gold standard

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy Treatment for neuroendocrine tumors

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Former South African nuclear executives to appeal suspensions in court Involves monthslong shutdown of NTP Radioisotopes medical isotope plant

FDA grants Fast Track designation to 64-Cu-Dotatate Used in PET diagnostic exams for suspected neuroendocrine tumors

Editorial takes aim at NRC efforts to lower the bar for nuclear medicine providers 'The NRC has abdicated its role as a protection agency for patients' say authors

Denos Health Management
launches Zionexa

Following Cyclopharma sale, Denos launches radiopharmaceutical company, Zionexa

por John R. Fischer , Staff Reporter
Denos Health Management, the former primary stakeholder of PET diagnostics manufacturer Cyclopharma France and U.S., is starting from scratch in the radiopharmaceutical industry following its sale of the French-based enterprise, with the launch of Zionexa.

Formerly the U.S. division of Cyclopharma, the new company will focus on clinically developing and commercializing innovative companion diagnostic and therapeutic radiopharmaceuticals to enhance patient care. Its establishment follows the recent acquisition of Cyclopharma by Curium.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510



“It was the right time,” Peter Webner, Zionexa CEO and former CEO of Cyclopharma U.S., told HCB News. “They were looking to get their equity out. Curium was looking at growing its footprint and a decision was made at the board level for Cyclopharma that they wanted to focus on the new products coming down the pipe.”

Announced in April and completed in May, the deal provided Curium access to nearly 100 employees and seven PET radiopharmacies throughout France, enabling it "comprehensive coverage of all 140 PET centers across France,” as stated in its announcement of the transaction.

Existing R&D and international operations of Cyclopharama though were not included in the agreement.

In addition to acquiring Cyclopharma’s U.S. division, Denos Health Management purchased the rights to the pipeline of Cyclopharma France, including EstroTep, a PET tracer cleared for use only in France.

Denos Health Management also adds value from early pharmacodynamics studies (Phase 0), early human kinetics and dosimetry and proof of concept imaging (Phase 1), target development and process and chemistry improvement (Phase 2), pivotal clearance trials (Phase 3), commercialization and distribution, and market access strategy.

Zionexa plans to gain FDA clearance for EstroTep and is currently working on clinical trials for several other products including IMAKinib, designed to target the EGFR protein in lung cancer.

A third product is also in the works. Webner could not comment on it at this time but did say that all three are fluorine-based and would “fit naturally into the mix of commercial and academic cyclotron capabilities in the U.S.”

EstroTep is planned as the first of the three to be submitted to the FDA for market clearance.

Submissions are set to begin this summer.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Directorio
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Trabajos/Entrenamiento
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS LOS DERECHOS RESERVADOS